MannKind Corp (MNKD) reported earnings for the third quarter of fiscal 2025, delivering an EPS of $0.07, surpassing Wall Street's expectation of $0.02 by $0.05. Revenue matched expectations at $0.1 billion.
The company, headquartered in Danbury, Connecticut, specializes in developing innovative therapeutic products for serious medical needs, particularly in the areas of cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza, an inhaled insulin product, and Tyvaso DPI, used for treating pulmonary arterial hypertension.
MannKind will host an earnings conference call to discuss these results and provide further insights into its business performance.
With a market cap of $1.75 billion and a P/E ratio of 54.16, MannKind continues to focus on addressing unmet medical needs in diabetes and pulmonary hypertension. Investors may want to review the full earnings release and management commentary for a comprehensive understanding of the quarter's performance and future outlook. Upcoming earnings are scheduled for May 5, 2026, with an estimated EPS of -0.0051 and revenue of $0.1 billion.